A Phase II Single-Arm Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Lenvatinib and TACE for Advanced Hepatocellular Carcinoma

​ Conditions: Hepatocellular Carcinoma (HCC)

Interventions: Drug: First-line Cohort; Drug: Second-line Cohort

Sponsors: The Second Affiliated Hospital of Shandong First Medical University

Not yet recruiting Conditions: Hepatocellular Carcinoma (HCC)
Interventions: Drug: First-line Cohort; Drug: Second-line Cohort
Sponsors: The Second Affiliated Hospital of Shandong First Medical University
Not yet recruiting